Results 71 to 80 of about 22,586,581 (189)
Treatment of Diffuse Large B-Cell Lymphoma
Journal of Clinical and Experimental Hematopathology, 2016 Diffuse large B-cell lymphoma (DLBCL) comprises a heterogeneous group with pathophysiological, genetic and clinical features. Many patients can be cured with R-CHOP therapy, which is the current standard regimen. Despite recent progress in improving patient survival, the 40% survival of DLBCL patients remains poor.
openaire +3 more sources
A Case of a Rapidly Progressive Small Bowel Lymphoma with High Ki-67 Expression
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017 Primary intestinal lymphoma is a rare disease. It accounts for approximately 1∼4% of gastrointestinal malignancy. Extranodal lymphoma of the intestine mainly arises from B cells.
Jiyeon Yoo +7 more
doaj +1 more source
Treatment of Diffuse Large B Cell Lymphoma
The Korean Journal of Internal Medicine, 2012 Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in combination with chemotherapy.
openaire +2 more sources
Diffuse large B-cell lymphoma of the small intestine in a patient with refractory coeliac disease. [PDF]
, 2019 INTRODUCTION: Coeliac disease enteropathy is associated with an increased risk of lymphomas. Enteropathy-associated T-cell lymphoma is the principal malignancy related to coeliac disease.
Raja Ali, Raja Affendi +4 more
core +1 more source
Diagnosis and treatment of diffuse large B-cell lymphoma
Swiss Medical Weekly, 2012 Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituximab typically in combination with cyclophosphamide ...
Mey, U +8 more
openaire +3 more sources
A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party [PDF]
, 1991 Between 1979 and 1987 the Scotland and Newcastle Lymphoma Group registered 972 adults with Working Formulation high or intermediate grade non-Hodgkin's lymphoma.
Leonard, R C +2 more
core
, 2017 Primary gastric diffuse large B-cell lymphomas may or may not have a concurrent component of mucosa-associated lymphoid tissue lymphoma. Diffuse large B-cell lymphoma/mucosa-associated lymphoid tissue lymphomas are often associated with Helicobacter ...
林中梧;郭頌鑫;鄭安理 +1 more
core +1 more source
Large cell lymphoma : correlation of HIV status and prognosis with differentiation profiles assessed by immunophenotyping [PDF]
, 2011 Includes abstract.Includes bibliographical references (leaves 80-93).The study aimed to contribute a South African perspective by correlating the HIV status and prognosis of DLBCL and PBL with differentiation profiles assessed by ...
Pather, Sugeshnee
core +1 more source
Haematologica, 2017 Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes +11 more
doaj +1 more source
Diffuse Large B Cell Lymphoma of the Foot in a Patient with Rheumatoid Arthritis [PDF]
, 2015 Patients with rheumatoid arthritis (RA) have an increased risk of developing malignant lymphomas, especially non-Hodgkin’s lymphoma (NHL). However, primary lymphoma in a joint is rare.
Madeleine Sampson +3 more
core